Divi's Laboratories delivered exceptional first quarter results for FY27, with consolidated net profit jumping 66% year-on-year to ₹902 crore, compared with ₹545 crore in the year-ago period. According to reports from Business Standard, the pharmaceutical major's revenue from operations increased 27.80% year-on-year to ₹3,080 crore in Q1 FY27, up from ₹2,410 crore in the same quarter last year. The company's profit before tax (PBT) stood at ₹1,180 crore, up 60.98% YoY from ₹733 crore in the corresponding quarter last year. The latest data confirms the strong performance trajectory with net profit rising 66% and sales increasing 27.80%, significantly beating analyst expectations with net profit exceeding the poll expectation of ₹657 crore and revenue surpassing the estimated ₹2,911 crore. The board meets on August 1, 2026, to approve unaudited results for the quarter ended June 30, 2026, followed by an earnings call at 2:00 PM IST.
The company's Earnings before interest, taxes, depreciation and amortisation (EBITDA) jumped 72.2% year-on-year to ₹1,255 crore from ₹729 crore a year ago, as reported by CNBC TV18. The EBITDA figure was significantly ahead of the CNBC-TV18 poll estimate of ₹915 crore. EBITDA margin expanded to 40.7% in Q1 FY27 from 30.2% in the corresponding quarter last year, with the margin also surpassing the CNBC-TV18 poll estimate of 31.4%. According to Business Standard, Operating Profit Margin (OPM) improved to 40.75% in Q1 FY27 from 30.25% in the previous year, demonstrating enhanced operational efficiency. The improvement in profitability was led by strong revenue growth and operating performance, with EBITDA margin expansion reflecting better earnings conversion during the quarter. JM Financial called it a "blockbuster quarter" with revenue, EBITDA and PAT beating Street estimates by 12%, 43% and 39% respectively, while Citi highlighted that product validation is driving a strong operational beat and noted that scaling commercial volumes could fundamentally transform the company's earnings trajectory. The Street believes the exceptionally strong quarter may have been aided by one-off milestone or validation batch payments under custom synthesis contracts, contributing to the sharp jump in margins.
Divi's Laboratories shares surged 5% to hit a new high of ₹8,464 on the BSE in Tuesday's intra-day trade after the company reported strong earnings for the April to June 2026 quarter (Q1FY27). As per Business Standard, the stock surpassed its previous high of ₹8,087 touched on July 31, 2026, with the pharma stock surpassing its previous high of ₹8,087 touched on July 31, 2026. In the past week, the market price of Divis Labs surged 14%, while in the past month, the stock outperformed the market by soaring 25%, as against a 1.2% rise in the BSE Sensex. In the past six months, it zoomed 36% compared to 6% decline in the benchmark index. At 11:35 AM on Monday, with ₹2.25 trillion market cap Divis Labs stood at 41st position in the overall market cap ranking. The company surpassed Eicher Motors and Hindalco in market capitalisation (market cap) after a sharp rally in the stock price, with Hindalco Industries' and Eicher Motors' market cap stood at ₹2.22 trillion and ₹2.21 trillion, respectively. Divi's Labs is now the second-most valuable listed pharmaceutical company after Sun Pharmaceutical Industries, which has a market cap of ₹4.7 trillion, followed by Torrent Pharmaceutical (₹1.92 trillion), Cipla (₹1.19 trillion), Zydus Lifesciences (₹1.11 trillion), Lupin (₹1.09 trillion) and Mankind Pharma (₹1.03 trillion).
Citi maintained its 'Buy' rating and upgraded its target price to ₹11,700 from ₹9,450, naming Divi's as its top India pharma pick. The brokerage raised earnings estimates by 8-15% following the strong Q1 performance and highlighted that scaling commercial volumes could fundamentally transform the company's earnings trajectory. JM Financial retained its 'Buy' rating with a target of ₹9,799, calling it a "blockbuster quarter" with revenue, EBITDA and PAT beating Street estimates by 12%, 43% and 39% respectively. Jefferies upgraded its target to ₹10,200 while maintaining a 'Buy' rating, citing the earnings beat driven by 50% growth in the Custom Synthesis business and healthy growth in nutraceuticals. Goldman Sachs recommended 'Accumulate' and raised its target to ₹9,070, noting the quarter as a strong indicator of earnings potential as large synthesis programmes move toward commercial supply. JPMorgan maintained its 'Overweight' rating with a target price of ₹9,100, acknowledging the quarter benefited from validation batch shipments while remaining constructive on the long-term peptide opportunity. However, Kotak Institutional Equities maintained its 'Sell' rating with a revised target of ₹6,925, cautioning that the quarterly gross margin surge of 750 basis points may not be fully sustainable given the lumpy nature of validation batch supplies, and flagging stretched valuations at 37x FY28 EV/EBITDA. Of the 33 analysts covering Divi's Labs, 16 have a 'Buy' rating, seven have a 'Hold' recommendation, while 10 have a 'Sell' call on the stock.
Custom Synthesis remained the key growth engine, accounting for around 60% of revenue after growing 45% year-on-year, as reported by CNBC TV18. The business segment's strong performance was supported by supplies of validation batches for dedicated capex projects. Macquarie attributed the strong performance to the 45% year-on-year growth in the Custom Synthesis business, which accounted for nearly 60% of revenue. The company reiterated its confidence in delivering double-digit growth for the year, even as it expects quarterly earnings to remain uneven because of the project-based nature of the business. Citi expects multiple projects, including three major capex programmes and the peptide business, to transition from validation to commercial production over the coming quarters, which could further improve profitability. The brokerage also sees contrast media volumes ramping up meaningfully while the peptide pipeline continues to strengthen. Management said it continues to focus on maintaining a balanced product portfolio without excessive dependence on any single product, customer or supply chain, while highlighting its differentiated position in peptides through a fully integrated manufacturing platform. Commercial supplies for the three dedicated CS projects (₹1,400 crore) worth assets capitalised so far are likely to begin in the next few quarters as clients receive regulatory clearances, with near-term growth may be boosted by supplies of contrast media products to two new customers.
While strong custom synthesis growth, peptide opportunities and higher earnings estimates support Divi's outlook, elevated valuations could restrict further stock upside according to recent market analysis. Systematix Research maintained a 'Hold' rating with a target price of ₹7,959, noting that the sharp run-up in the stock largely reflects the improving business outlook, limiting meaningful upside from current levels. ICICI Securities downgraded the stock to a 'Sell' rating with a target price of ₹6,500, despite being positive about opportunities in custom synthesis projects, as it believes the current valuation adequately factors in the medium-term opportunity. The operational performance also exceeded expectations, with gross profit rising 44% and gross margins expanding by 766 basis points Y-o-Y to 68% due to a richer custom synthesis mix and favourable inventory movement. Operating profit grew 72% Y-o-Y, while operating profit margins expanded by 1,050 basis points Y-o-Y to 41% on superior operating leverage and manufacturing efficiencies. The company reiterated its confidence in sustaining double-digit revenue growth over the medium term, supported by the commercialisation of validation projects, peptide opportunities, ongoing capacity additions, and continued momentum in the custom synthesis business.
